BeiGene Announces US FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

BeiGene announced that the US FDA has accepted a supplemental new drug application or BRUKINSA® for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.